Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lipodox vs Caelyx in Breast/Ovarian Cancer
NCT05273944Phase 1Unknown
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer and ovarian cancer (2 arms), sponsored by Shenzhen Kangzhe Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT05273944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273944.